General Topics -- DARPP-32 Mediates the Actions of Multiple Drugs of Abuse -- Drug Discovery From Natural Sources -- Computational Methods in Drug Design: Modeling G Protein-Coupled Receptor Monomers, Dimers, and Oligomers -- Symbiotic Relationship of Pharmacogenetics and Drugs of Abuse -- Monoclonal Antibody Form and Function: Manufacturing the Right Antibodies for Treating Drug Abuse -- Cocaine- and Amphetamine-Regulated Transcript Peptides Play a Role in Drug Abuse and Are Potential Therapeutic Targets -- RNAi-Directed Inhibition of DC-SIGN by Dendritic Cells: Prospects for HIV-1 Therapy -- Viewing Chemokines as a Third Major System of Communication in the Brain -- Targeting the PDZ Domains of Molecular Scaffolds of Transmembrane Ion Channels -- Neuronal Nicotinic Acetylcholine Receptor Expression and Function on Nonneuronal Cells -- Transporters & Stimulants & Hallucinogens -- Role of Monoamine Transporters in Mediating Psychostimulant Effects -- Development of the Dopamine Transporter Selective RTI-336 as a Pharmacotherapy for Cocaine Abuse -- Serotonin Transporters: Implications for Antidepressant Drug Development -- Recent Advances for the Treatment of Cocaine Abuse: Central Nervous System Immunopharmacotherapy -- ? Opioids as Potential Treatments for Stimulant Dependence -- Regulation of Monoamine Transporters: Influence of Psychostimulants and Therapeutic Antidepressants -- Hallucinogen Actions on 5-HT Receptors Reveal Distinct Mechanisms of Activation and Signaling by G Protein-Coupled Receptors -- Recognition of Psychostimulants, Antidepressants, and Other Inhibitors of Synaptic Neurotransmitter Uptake by the Plasma Membrane Monoamine Transporters -- Dual Dopamine/Serotonin Releasers as Potential Medications for Stimulant and Alcohol Addictions -- Receptors of Mammalian Trace Amines -- Drug Design: Nicotine, Opioids and Related Ligands -- The Role of Crystallography in Drug Design -- Opioid Peptide-Derived Analgesics -- Opioid Ligands with Mixed ?/? Opioid Receptor Interactions: An Emerging Approach to Novel Analgesics -- Small-Molecule Agonists and Antagonists of the Opioid Receptor-Like Receptor (ORL1, NOP): Ligand-Based Analysis of Structural Factors Influencing Intrinsic Activity at NOP -- Kappa Opioid Antagonists: Past Successes and Future Prospects -- In Vitro and Direct In Vivo Testing of Mixture-Based Combinatorial Libraries for the Identification of Highly Active and Specific Opiate Ligands -- Current Status of Immunologic Approaches to Treating Tobacco Dependence: Vaccines and Nicotine-Specific Antibodies -- New Paradigms and Tools in Drug Design for Pain and Addiction -- Opioids: General -- Neuropeptide-Processing Enzymes: Applications for Drug Discovery -- CNS Drug Delivery: Opioid Peptides and the Blood-Brain Barrier -- Cell-Permeable, Mitochondrial-Targeted, Peptide Antioxidants -- Targeting Opioid Receptor Heterodimers: Strategies for Screening and Drug Development -- Homology Modeling of Opioid Receptor-Ligand Complexes Using Experimental Constraints -- Molecular Recognition of Opioid Receptor Ligands -- Role of Morphine's Metabolites in Analgesia: Concepts and Controversies -- Mu Opioid Receptor Regulation and Opiate Responsiveness -- Agmatine: Biological Role and Therapeutic Potentials in Morphine Analgesia and Dependence -- Cannabinoid -- The Therapeutic Potential of Drugs that Target Cannabinoid Receptors or Modulate the Tissue Levels or Actions of Endocannabinoids -- Further Advances in the Synthesis of Endocannabinoid-Related Ligands -- Ajulemic Acid (IP-751): Synthesis, Proof of Principle, Toxicity Studies, and Clinical Trials -- Conformational Characteristics of the Interaction of SR141716A with the CB1 Cannabinoid Receptor as Determined Through the Use of Conformationally Constrained Analogs -- Activation of G-Proteins in Brain by Endogenous and Exogenous Cannabinoids -- 2-Arachidonoylglycerol (2-AG) Membrane Transport: History and Outlook -- Endocannabinoid Mechanisms of Pain Modulation. Drug Addiction: From Basic Research to Therapy provides a comprehensive overview of physiological, biochemical, genetic and behavioral pathways underlying drug addiction. Focusing on fundamental neurophysiological processes that overlap between drug addiction and other CNS disorders, this volume covers the translation of basic research into novel therapies, not only of drug addiction but a spectrum of related CNS disorders, including pain. Chapters are written by leading scientists with widely ranging expertise in synthetic and computational chemistry, molecular biology, genetics, neurosciences, drug discovery and development, drug targeting, and quantitative therapeutics, providing an unprecedented overview of a complex field of high societal signficance.